Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-Center Study of High Dose Aldesleukin (Interleukin-2) + Vemurafenib Therapy in Patients With BRAFV600 Mutation Positive Metastatic Melanoma

NCT01683188 is registered in ClinicalTrials.gov with Clinigen, Inc. as lead sponsor.

NCT NCT01683188
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01683188 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-Center Study of High Dose Aldesleukin (Interleukin-2) + Vemurafenib Therapy in Patients With BRAFV600 Mutation Positive Metastatic Melanoma
Lead sponsor
Clinigen, Inc.
Phase
Phase 4
Overall status
Terminated
Start date
August 31, 2012
Completion date
November 30, 2014
Enrollment
53 (actual)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic melanoma